Stem cell treatments are often promoted as a way to repair damaged tissue, ease chronic pain or even reverse disease, but some therapies being offered to patients remain unapproved and lack the clinical evidence needed to establish whether they are safe or effective.

The issue is gaining renewed attention as parts of the stem cell industry push for a regulatory pathway that could bring commercially available therapies closer to the mainstream. The push comes as the FDA takes a more accommodating approach to compounded peptides, which some stem-cell entrepreneurs see as a potential model for their own industry.

A recent STAT report found that stem cell entrepreneurs see the Food and Drug Administration's changing approach to peptides as an opportunity to seek greater regulatory acceptance for stem cell products currently operating in what the industry describes as a grey market.

For patients, however, the distinction between an experimental therapy and an approved treatment remains critical.

What Are Stem Cell Treatments Supposed to Do?

Stem cells are cells capable of developing into other cell types and, depending on the type of stem cell, can contribute to tissue maintenance and repair.

That ability has fuelled interest in regenerative medicine, an area that aims to restore or replace damaged cells, tissues or organs rather than simply manage symptoms.

Researchers are studying stem cell-based treatments for a wide range of conditions. But promising biological mechanisms do not automatically translate into effective treatments.

The International Society for Stem Cell Research distinguishes between approved treatments, investigational treatments being studied in properly regulated clinical trials, and unproven interventions. It warns that many commercially marketed stem cell treatments have not undergone the rigorous testing needed to demonstrate safety and effectiveness.

The FDA Has Warned About Unapproved Products

In the United States, the FDA regulates stem cell products and generally requires them to be approved before they can be marketed as treatments.

Currently, the FDA says the only stem cell products it has approved for use in the U.S. consist of blood-forming stem cells derived from umbilical cord blood. These products are approved for specific disorders affecting the blood-forming system, not for the broad range of conditions for which clinics may promote other stem cell products.

The agency has repeatedly warned consumers about products marketed as regenerative medicine therapies for conditions including arthritis, back pain, neurological disorders, cardiovascular disease and chronic pain.

Some clinics have marketed products derived from umbilical cord tissue, amniotic fluid, fat tissue or other biological sources as treatments for conditions that have not been established through adequate clinical evidence.

FDA enforcement has continued in 2026. In September, the agency issued a warning letter to a company manufacturing an umbilical cord blood-derived cell product that it determined was an unapproved new drug and unlicensed biological product.

Read more

What Can Go Wrong With Unproven Stem Cell Therapy?

The risks can extend beyond a treatment simply failing to work.

The FDA has reported serious complications associated with unapproved regenerative medicine products, infections, immune reactions, blindness and abnormal tissue growth. In some cases, cells can move to unintended areas of the body or develop into unwanted tissue.

There is also a risk of contamination during the collection, processing or administration of cellular products. Because these therapies can involve human cells or tissues, maintaining sterility and controlling exactly what is being administered are important parts of patient safety.

In 2026, the FDA also warned about serious risks associated with unapproved products made from human cells or tissues after receiving reports of adverse events, including a patient death following use of an imported human placental tissue-derived product that had not been approved by the agency. The report did not establish that the product caused the death, but it prompted the FDA to reiterate its warning against using unapproved products marketed online.

Does Regulatory Approval Mean Stem Cells Are Ready for Everyone?

Not necessarily.

Regulatory approval means a specific product has undergone the regulatory review required for its particular use. It does not mean every treatment described as 'stem cell therapy' has the same evidence behind it.

Likewise, being investigated in a clinical trial does not mean a therapy has already been shown to work. Clinical trials are designed to determine whether a treatment is safe and effective, and many experimental therapies ultimately fail to demonstrate sufficient benefit.

That distinction is particularly important as the industry seeks a clearer pathway for products that are already being marketed to consumers.

For patients considering a stem cell treatment, the key questions are whether the specific product is authorised for the condition being treated, whether it is being administered as part of a properly regulated clinical trial, and what evidence supports its safety and effectiveness.

The promise of regenerative medicine remains substantial, but the ability to repair damaged tissue in a laboratory is not the same as proving that a treatment can safely repair the human body.

Frequently Asked Questions

  • What are stem cell treatments supposed to do?
    Stem cell treatments aim to restore or replace damaged cells, tissues, or organs rather than simply manage symptoms.
  • What are the risks of unproven stem cell therapy?
    Risks include infections, immune reactions, neurological events, blindness, abnormal tissue growth, and contamination during collection, processing, or administration.
  • Does regulatory approval mean stem cells are ready for everyone?
    Regulatory approval indicates a product has met required standards for its use, but not all stem cell therapies have the same evidence or approval.
  • What should patients consider before undergoing stem cell treatment?
    Patients should consider whether the product is authorised for their condition, if it is part of a regulated clinical trial, and what evidence supports its safety and effectiveness.
Read more